Page last updated: 2024-12-08

1-(3-(4-chlorobenzoyl)propyl)-4-hydroxy-4-(4-chlorophenyl)piperidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-(3-(4-chlorobenzoyl)propyl)-4-hydroxy-4-(4-chlorophenyl)piperidine is a **synthetic compound** with the **chemical formula C20H22Cl2NO3**. It's a **complex molecule** with a **piperidine ring system**, a **hydroxy group**, and a **benzoyl group**.

**Why is it important for research?**

While the exact research interest in this specific compound isn't readily available without context, its structure suggests potential applications in **pharmacological research**. Here's why:

* **Piperidine ring system:** Piperidine is a common structural motif found in many drugs, especially **antidepressants** (e.g., fluoxetine) and **analgesics** (e.g., fentanyl).
* **Hydroxy group:** Hydroxy groups are often involved in **hydrogen bonding**, a crucial interaction for drug activity and binding to biological targets.
* **Benzoyl group:** Benzoyl groups are frequently incorporated into drugs to **modify their pharmacokinetic properties** (how the drug is absorbed, distributed, metabolized, and eliminated).

Given its structural features, 1-(3-(4-chlorobenzoyl)propyl)-4-hydroxy-4-(4-chlorophenyl)piperidine might be a **lead compound** for developing new drugs with potential applications in:

* **Neurological disorders:** The piperidine ring and hydroxy group suggest potential activity in the central nervous system.
* **Pain management:** The benzoyl group and piperidine ring could contribute to analgesic effects.
* **Other therapeutic areas:** Further research could reveal other potential applications.

**Important Note:** It's crucial to remember that this compound's specific purpose and research importance need to be determined through dedicated experimental studies. This information alone is not sufficient to conclude its exact role in research.

1-(3-(4-chlorobenzoyl)propyl)-4-hydroxy-4-(4-chlorophenyl)piperidine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID173712
CHEMBL ID363548
SCHEMBL ID4112719
MeSH IDM0121030

Synonyms (15)

Synonym
chlorohaloperidol
59995-68-5
CHEMBL363548 ,
bdbm50219049
1-(4-chlorophenyl)-4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)butan-1-one
1-(4-chloro-phenyl)-4-[4-(4-chloro-phenyl)-4-hydroxy-piperidin-1-yl]-butan-1-one
1-(4-chlorophenyl)-4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]butan-1-one
1-butanone, 1-(4-chlorophenyl)-4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-
1-(3-(4-chlorobenzoyl)propyl)-4-hydroxy-4-(4-chlorophenyl)piperidine
1-(4-chlorophenyl)-4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-butan-1-one
QETRGFJTEVVJTC-UHFFFAOYSA-N
4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-(4-chlorophenyl)-1-butanone
SCHEMBL4112719
DTXSID30208698
FT-0728550
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D(2) dopamine receptorHomo sapiens (human)Ki0.09750.00000.651810.0000AID1616723; AID297277
Alpha-1A adrenergic receptorHomo sapiens (human)Ki0.15000.00000.272610.0000AID297276
Melanin-concentrating hormone receptor 1Rattus norvegicus (Norway rat)Ki0.35000.00030.07060.3500AID297275
N-acetyltransferase EisMycobacterium tuberculosis H37RvIC50 (µMol)5.10000.39001.64255.1000AID1853637
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D(2) dopamine receptorHomo sapiens (human)Kd0.00500.00000.64599.5000AID1616723
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Melanin-concentrating hormone receptor 1Homo sapiens (human)Kb0.00900.00900.00900.0090AID238112
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (132)

Processvia Protein(s)Taxonomy
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
apoptotic processAlpha-1A adrenergic receptorHomo sapiens (human)
smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
activation of phospholipase C activityAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1A adrenergic receptorHomo sapiens (human)
adult heart developmentAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of cell population proliferationAlpha-1A adrenergic receptorHomo sapiens (human)
response to xenobiotic stimulusAlpha-1A adrenergic receptorHomo sapiens (human)
response to hormoneAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of autophagyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of action potentialAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
calcium ion transport into cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
cell growth involved in cardiac muscle cell developmentAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase C signalingAlpha-1A adrenergic receptorHomo sapiens (human)
pilomotor reflexAlpha-1A adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
symbiont-mediated suppression of host defense-related programmed cell deathN-acetyltransferase EisMycobacterium tuberculosis H37Rv
generation of precursor metabolites and energyMelanin-concentrating hormone receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayMelanin-concentrating hormone receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMelanin-concentrating hormone receptor 1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayMelanin-concentrating hormone receptor 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationMelanin-concentrating hormone receptor 1Homo sapiens (human)
feeding behaviorMelanin-concentrating hormone receptor 1Homo sapiens (human)
positive regulation of calcium ion transportMelanin-concentrating hormone receptor 1Homo sapiens (human)
neuropeptide signaling pathwayMelanin-concentrating hormone receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1A adrenergic receptorHomo sapiens (human)
N-acetyltransferase activityN-acetyltransferase EisMycobacterium tuberculosis H37Rv
signaling receptor bindingMelanin-concentrating hormone receptor 1Homo sapiens (human)
neuropeptide receptor activityMelanin-concentrating hormone receptor 1Homo sapiens (human)
melanin-concentrating hormone receptor activityMelanin-concentrating hormone receptor 1Homo sapiens (human)
hormone bindingMelanin-concentrating hormone receptor 1Homo sapiens (human)
G protein-coupled receptor activityMelanin-concentrating hormone receptor 1Homo sapiens (human)
neuropeptide bindingMelanin-concentrating hormone receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (29)

Processvia Protein(s)Taxonomy
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
nucleusAlpha-1A adrenergic receptorHomo sapiens (human)
nucleoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
caveolaAlpha-1A adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
cytosolN-acetyltransferase EisMycobacterium tuberculosis H37Rv
plasma membraneMelanin-concentrating hormone receptor 1Homo sapiens (human)
ciliumMelanin-concentrating hormone receptor 1Homo sapiens (human)
ciliary membraneMelanin-concentrating hormone receptor 1Homo sapiens (human)
non-motile ciliumMelanin-concentrating hormone receptor 1Homo sapiens (human)
neuron projectionMelanin-concentrating hormone receptor 1Homo sapiens (human)
plasma membraneMelanin-concentrating hormone receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID1853674Antibacterial activity against Mycobacterium intracellulare ATCC 13950 in presence of clarithromycin by checkerboard assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853676Antibacterial activity against Mycobacterium avium ATCC 25921 in presence of spectinomycin by checkerboard assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853668Synergistic antibacterial activity against Mycobacterium smegmatis mc2 155 assessed as fold reduction in MIC value at 8 ug/ml in presence of clarithromycin by checkerboard assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1616727Agonist activity at SNAP-tagged human D2LR expressed in Flp-In CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation at 10 uM measured after 10 mins in presence of coelenterazine by BRET assay relative to control
AID1616723Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay
AID1853649Antibacterial activity against Mycobacterium smegmatis mc2 155 assessed as inhibition of bacterial growth incubated upto 3 weeks hrs by resazurin dye based double-dilution method2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853637Inhibition of Mycobacterium tuberculosis Eis assessed as Eis-mediated kanamycin acetylation preincubated for 10 mins followed by substrate addition and measured for 2 to 5 mins using acetyl-CoA as substrate in presence of kanamycin by UV-Vis spectroscopy 2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853681Antibacterial activity against Mycobacterium bovis BCG ATCC 35734 in presence of clarithromycin by checkerboard assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID297276Displacement of [125I]HEAT from human recombinant adrenergic alpha-1A receptor2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists part 2: A hybrid strategy combining key fragments of HTS hits.
AID297277Displacement of [3H]spiperone from human recombinant dopamine D2 receptor2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists part 2: A hybrid strategy combining key fragments of HTS hits.
AID1616722Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes assessed as dissociation half-life by TR-FRET assay
AID1853648Inhibition of Mycobacterium tuberculosis AAC(2')-Ic at 200 uM using NEO as substrate in presence of Acetyl-CoA by UV-Vis spectroscopy analysis2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1616728Antagonist activity at SNAP-tagged human D2LR expressed in Flp-In CHO cells assessed as suppression of dopamine-induced inhibition of forskolin-stimulated cAMP accumulation at 10 uM preincubated with compound followed by forskolin and dopamine addition an
AID1853671Synergistic antibacterial activity against Mycobacterium abscessus ATCC 19977 in presence of clarithromycin by checkerboard assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853689Cytotoxicity against human A549 cells assessed as reduction in cell viability at 200 uM incubated for 24 hrs by resazurin assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853670Synergistic antibacterial activity against Mycobacterium abscessus ATCC 19977 assessed as reduction in bacterial growth presence of spectinomycin by checkerboard assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853678Antibacterial activity against Mycobacterium avium ATCC 25921 in presence of clarithromycin by checkerboard assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853675Antibacterial activity against Mycobacterium intracellulare ATCC 13950 in presence of clofazimine by checkerboard assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID297275Displacement of [3H]T-226296 from rat recombinant MCH1 receptor2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists part 2: A hybrid strategy combining key fragments of HTS hits.
AID238112Binding affinity for Melanin-concentrating hormone 1 receptor expressed in CHO cells2004Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16
A virtual screening approach to finding novel and potent antagonists at the melanin-concentrating hormone 1 receptor.
AID1853651Antibacterial activity against Mycobacterium intracellulare ATCC 13950 assessed as inhibition of bacterial growth incubated upto 3 weeks hrs by resazurin dye based double-dilution method2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853673Antibacterial activity against Mycobacterium intracellulare ATCC 13950 in presence of spectinomycin by checkerboard assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853667Synergistic antibacterial activity against Mycobacterium smegmatis mc2 155 assessed as fold reduction in MIC value at 8 ug/ml in presence of spectinomycin by checkerboard assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853650Antibacterial activity against Mycobacterium abscessus ATCC 19977 assessed as inhibition of bacterial growth incubated upto 3 weeks hrs by resazurin dye based double-dilution method2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1616720Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes assessed as association rate constant by TR-FRET assay
AID1853647Inhibition of Mycobacterium tuberculosis AAC(3')-IV at 200 uM using NEO as substrate in presence of Acetyl-CoA by UV-Vis spectroscopy analysis2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853679Antibacterial activity against Mycobacterium avium ATCC 25921 in presence of clofazimine by checkerboard assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1616721Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes assessed as dissociation rate constant by TR-FRET assay
AID1853652Antibacterial activity against Mycobacterium avium ATCC 25921 assessed as inhibition of bacterial growth incubated upto 3 weeks hrs by resazurin dye based double-dilution method2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853680Synergistic antibacterial activity against Mycobacterium bovis BCG ATCC 35734 in presence of spectinomycin by checkerboard assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853686Cytotoxicity against human HEK293 cells assessed as reduction in cell viability at 200 uM incubated for 24 hrs by resazurin assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853683Synergistic antibacterial activity against Mycobacterium tuberculosis H37Ra ATCC NRS22 in presence of spectinomycin by checkerboard assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853654Antibacterial activity against Mycobacterium tuberculosis H37Ra ATCC NRS22 assessed as inhibition of bacterial growth incubated upto 3 weeks hrs by resazurin dye based double-dilution method2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853646Inhibition of Mycobacterium tuberculosis AAC(6')-Ie/APH(2'')-Ia assessed as inhbition at AAC(6')-Ie at 200 uM using NEO as substrate in presence of Acetyl-CoA by UV-Vis spectroscopy analysis2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853672Synergistic antibacterial activity against Mycobacterium abscessus ATCC 19977 in presence of clofazimine by checkerboard assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853669Synergistic antibacterial activity against Mycobacterium smegmatis mc2 155 assessed as fold reduction in MIC value at 8 ug/ml in presence of clofazimine by checkerboard assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853655Antibacterial activity against Mycobacterium tuberculosis mc2 6230 with Eis C-14T mutation assessed as inhibition of bacterial growth incubated upto 3 weeks hrs by resazurin dye based double-dilution method2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853682Antibacterial activity against Mycobacterium bovis BCG ATCC 35734 in presence of clofazimine by checkerboard assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853653Antibacterial activity against Mycobacterium bovis BCG ATCC 35734 assessed as inhibition of bacterial growth incubated upto 3 weeks hrs by resazurin dye based double-dilution method2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
AID1853691Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell viability at 50 uM incubated for 24 hrs by resazurin assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (36.36)18.7374
1990's3 (27.27)18.2507
2000's2 (18.18)29.6817
2010's1 (9.09)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.75 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]